Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Patrick R. Harrington
Observed names:
P Harrington,
P. Harrington,
Patrick Harrington,
Patrick R Harrington,
Patrick R. Harrington
Institutions:
United States Food and Drug Administration,
Center for Drug Evaluation and Research
Observed institutions:
University of North Carolina at Chapel Hill,
United States Food and Drug Administration,
Center for Drug Evaluation and Research,
UNC Lineberger Comprehensive Cancer Center
ORCID:
0009-0006-1667-4546
Observed ORCID:
0009-0006-1667-4546
OpenAlex ID:
A5009039571
Works
38
Awards
3
Binding of Norwalk Virus-Like Particles to ABH Histo-Blood Group Antigens Is Blocked by Antisera from Infected Human Volunteers or Experimentally Vaccinated Mice
2002
·
Patrick R. Harrington
, Lisa Lindesmith
, et al.
·
Journal of Virology
·
320
Hepatitis C virus drug resistance–associated substitutions: State of the art summary
2015
·
Erik Lontok
, Patrick Harrington
, et al.
·
Hepatology
·
295
PDF
Neurologic and neurodevelopmental manifestations of pediatric HIV/AIDS: A global perspective
2006
·
Annelies Van Rie
, Patrick R. Harrington
, et al.
·
European Journal of Paediatric Neurology
·
206
Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir
2014
·
Eric F. Donaldson
, Patrick R. Harrington
, et al.
·
Hepatology
·
189
Norovirus Capture with Histo-Blood Group Antigens Reveals Novel Virus-Ligand Interactions
2004
·
Patrick R. Harrington
, Jan Vinjé
, et al.
·
Journal of Virology
·
162
Multivalent norovirus vaccines induce strong mucosal and systemic blocking antibodies against multiple strains
2006
·
Anna D. LoBue
, Lisa Lindesmith
, et al.
·
Vaccine
·
161
Compartmentalized Human Immunodeficiency Virus Type 1 Originates from Long-Lived Cells in Some Subjects with HIV-1–Associated Dementia
2009
·
Gretja Schnell
, Serena Spudich
, et al.
·
PLoS Pathogens
·
158
PDF
Cross-sectional characterization of HIV-1 env compartmentalization in cerebrospinal fluid over the full disease course
2009
·
Patrick R Harrington
, Gretja Schnell
, et al.
·
AIDS
·
117
Expression and Self-Assembly of Norwalk Virus Capsid Protein from Venezuelan Equine Encephalitis Virus Replicons
2002
·
Ralph S. Baric
, Boyd Yount
, et al.
·
Journal of Virology
·
115
Systemic, Mucosal, and Heterotypic Immune Induction in Mice Inoculated with Venezuelan Equine Encephalitis Replicons Expressing Norwalk Virus-Like Particles
2002
·
Patrick R. Harrington
, Boyd Yount
, et al.
·
Journal of Virology
·
110
Benefit-risk assessment for brincidofovir for the treatment of smallpox: U.S. Food and Drug Administration's Evaluation
2021
·
Kirk Chan-Tack
, Patrick Harrington
, et al.
·
Antiviral Research
·
87
Resistance of human cytomegalovirus to ganciclovir/valganciclovir: A comprehensive review of putative resistance pathways
2013
·
Takashi E. Komatsu
, Andreas Pikis
, et al.
·
Antiviral Research
·
85
Clinical relevance of detectable but not quantifiable hepatitis C virus RNA during boceprevir or telaprevir treatment
2011
·
Patrick R. Harrington
, Wen Zeng
, et al.
·
Hepatology
·
76
Compartmentalized Human Immunodeficiency Virus Type 1 Present in Cerebrospinal Fluid Is Produced by Short-Lived Cells
2005
·
Patrick R. Harrington
, David W. Haas
, et al.
·
Journal of Virology
·
65
Regulatory Analysis of Effects of Hepatitis C Virus NS5A Polymorphisms on Efficacy of Elbasvir and Grazoprevir
2016
·
Takashi E. Komatsu
, Sarita Boyd
, et al.
·
Gastroenterology
·
59
Impact of hepatitis C virus polymorphisms on direct‐acting antiviral treatment efficacy: Regulatory analyses and perspectives
2017
·
Patrick R. Harrington
, Takashi E. Komatsu
, et al.
·
Hepatology
·
52
Effect of Dolutegravir Functional Monotherapy on HIV-1 Virological Response in Integrase Strand Transfer Inhibitor Resistant Patients
2015
·
Lisa K Naeger
, Patrick Harrington
, et al.
·
Antiviral Therapy
·
49
Assessing a drug for an eradicated human disease: US Food and Drug Administration review of tecovirimat for the treatment of smallpox
2019
·
Kirk M Chan-Tack
, Patrick R Harrington
, et al.
·
The Lancet Infectious Diseases
·
47
Sequence and Phenotypic Analysis for Resistance Monitoring in Hepatitis C Virus Drug Development: Recommendations From the HCV DRAG
2011
·
Ann D. Kwong
, Isabel Najera
, et al.
·
Gastroenterology
·
41
PDF
Sequencing of hepatitis C virus for detection of resistance to direct‐acting antiviral therapy: A systematic review
2017
·
Sofia R. Bartlett
, Jason Grebely
, et al.
·
Hepatology Communications
·
38
Independent Evolution of Human Immunodeficiency Virus Type 1 env V1/V2 and V4/V5 Hypervariable Regions during Chronic Infection
2007
·
Patrick R. Harrington
, Julie A. E. Nelson
, et al.
·
Journal of Virology
·
31
Evaluation of SARS-CoV-2 RNA Rebound After Nirmatrelvir/Ritonavir Treatment in Randomized, Double-Blind, Placebo-Controlled Trials — United States and International Sites, 2021–2022
2023
·
Patrick R. Harrington
, Jie Cong
, et al.
·
MMWR Morbidity and Mortality Weekly Report
·
27
PDF
Dynamics of Simian Immunodeficiency Virus Populations in Blood and Cerebrospinal Fluid over the Full Course of Infection
2007
·
Patrick R. Harrington
, Mary J. Connell
, et al.
·
The Journal of Infectious Diseases
·
25
Direct‐acting antiviral drugs for the treatment of chronic hepatitis C virus infection: Interferon free is now
2015
·
J Florian
, P Mishra
, et al.
·
Clinical Pharmacology & Therapeutics
·
21
Major Coexisting Human Immunodeficiency Virus Type 1envGene Subpopulations in the Peripheral Blood Are Produced by Cells with Similar Turnover Rates and Show Little Evidence of Genetic Compartmentalization
2009
·
William L. Ince
, Patrick R. Harrington
, et al.
·
Journal of Virology
·
20
Show more works
View as search
Works count:
38
Citation count:
2,667
H-index:
23
I10-index:
32
Year
Topic
Type